Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19.

Emerging infectious diseases - 1 Oct 2021

Focosi Daniele, Novazzi Federica, Genoni Angelo, Dentali Francesco, Gasperina Daniela Dalla, Baj Andreina, Maggi Fabrizio

Abstract excerpt

We report in vivo selection of a severe acute respiratory syndrome coronavirus 2 spike mutation (Q493R) conferring simultaneous resistance to bamlanivimab and etesivimab. This mutation was isolated from a patient who had coronavirus disease and was treated with these drugs.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19
Share to COVID-19 Clinical Research Studies
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to SARS-CoV-2

Share to SARS-CoV-2 and COVID-19 Research

Share to SARS-CoV-2 detection and testing

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 34314668
DOI: 10.3201/eid2710.211538
PMCID: PMC8462334

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19.PMID 34314668Read ↗

SELEX based aptamers with diagnostic and entry inhibitor therapeutic potential for SARS-CoV-2Semantic proximity Read ↗

SELEX based aptamers with diagnostic and entry inhibitor therapeutic potential for SARS-CoV-2Semantic proximity Read ↗

Neutralizing anti-spike monoclonal antibodies for COVID-19 in vulnerable populations: lessons learned and future directions.Semantic proximity Read ↗

Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial.Semantic proximity Read ↗

Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies.Semantic proximity Read ↗

Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection.Semantic proximity Read ↗

Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report.Semantic proximity Read ↗

Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2.Semantic proximity Read ↗

In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance.Semantic proximity Read ↗

RESISTANCE CONFERRING MUTATIONS IN SARS-CoV-2 DELTA FOLLOWING SOTROVIMAB INFUSIONSemantic proximity Read ↗

Inhibition of SARS-CoV-2 Infection in Human Airway Epithelium with a Xeno-Nucleic Acid AptamerSemantic proximity Read ↗

SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody MonotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.